Evidence map›Paper›PMID 30050877›Full record

ArticleTranslational medicine @ UniSa2017

siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease.

Ilaria Russo, Albino Carrizzo, Sabrina Bochicchio, Ornella Piazza, Gaetano Lamberti, Anna Angela Barba, Carmine Vecchione, Pio Zeppa, Paola Iovino, Cristina Bucci and 2 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Translational medicine @ UniSa, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ilaria RussoDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Albino CarrizzoDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Sabrina BochicchioDepartment of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY.
Ornella PiazzaDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Gaetano LambertiDepartment of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY.
Anna Angela BarbaDepartment of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY.
Carmine VecchioneDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Pio ZeppaDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Paola IovinoDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Cristina BucciDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Antonella SantonicolaDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
Carolina CiacciDepartment of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy.
University of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence in inflammatory bowel diseases (IBD) supports a connection between inflammation and cancer due to the alteration of the cell cycle with loss of control at the G1/S checkpoint. In this study, we analyze the expression and modulation of CyD1 and E2F1 in colon explants from Crohn's disease (CD) patients. We used ex vivo culture of colon explants from 4 CD patients and 2 healthy controls, stimulated with lipopolysaccharide from Escherichia Coli (EC-LPS). Commercial siRNAs for CyD1 and E2F1 inhibition were encapsulated in Invivofectamine® and in purposely produced nanoliposomal vectors to silencing CyD1 and E2F1 expression. Western blot analysis was used to investigate the effect of siRNA on CyD1, E2F1 and cyclooxygenase 2 (COX-2) expression. In CD patients colon explants, CyD1 and E2F1 increased after the inflammatory stimulus but siRNA silencing attenuated their expression and controlled the COX-2 expression too. These data represent a prelimiary exploration of in vitro siRNA use.

Indexed as

Crohn’s diseaseCyclin D1E2F1EC-LPS (Lipopolysaccharide from Escherichia Coli)IBD (inflammatory bowel disease)nanoliposomessiRNA

Identifiers

PMID30050877
PMCPMC6056255
OpenAlexW2971971590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.